MAPT and tauopathy: A low-molecular-weight OGA inhibitor, MK-8719, developed in a collaboration between Alectos Therapeutics and Merck, was found to elevate brain O-GlcNAc levels, reduce pathological tau, and ameliorate brain atrophy in an rTg4510 mouse model of tauopathy (Wang et al., 2020).